TRCT
ALGS icon

Tower Research Capital (TRC)’s Aligos Therapeutics ALGS Stock Holding History

Tower Research Capital (TRC)’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.07K Buy
359
+294
+452% +$1.82K ﹤0.01% 4725
2026
Q1 		$483 Buy
65
+26
+67% +$197 ﹤0.01% 4855
2025
Q4 		$363 Sell
39
-418
-91% -$3.94K ﹤0.01% 4927
2025
Q3 		$4.48K Sell
457
-646
-59% -$5.9K ﹤0.01% 4343
2025
Q2 		$7.95K Sell
1,103
-118
-10% -$706 ﹤0.01% 4029
2025
Q1 		$10.1K Buy
1,221
+569
+87% +$12.5K ﹤0.01% 3680
2024
Q4 		$26K Buy
652
+622
+2,073% +$12K ﹤0.01% 2985
2024
Q3 		$260 Sell
30
-1,829
-98% -$22.8K ﹤0.01% 5407
2024
Q2 		$16.3K Buy
1,859
+1,538
+479% +$27K ﹤0.01% 3868
2024
Q1 		$7.86K Sell
321
-428
-57% -$8.52K ﹤0.01% 4123
2023
Q4 		$12.4K Buy
+749
New +$12.9K ﹤0.01% 4043
2023
Q2 		– Sell
-4
Closed – – 6019
2023
Q1 		$0 Buy
+4
New +$153 ﹤0.01% 5765
2022
Q4 		– Sell
-322
Closed -$9K – 5846
2022
Q3 		$9K Sell
322
-424
-57% -$14.1K ﹤0.01% 4629
2022
Q2 		$22K Buy
746
+550
+281% +$18.7K ﹤0.01% 3679
2022
Q1 		$11K Buy
196
+118
+151% +$9.45K ﹤0.01% 4138
2021
Q4 		$23K Buy
78
+43
+123% +$15.7K ﹤0.01% 3497
2021
Q3 		$14K Sell
35
-24
-41% -$9.49K ﹤0.01% 4018
2021
Q2 		$30K Buy
59
+27
+84% +$17.2K ﹤0.01% 3475
2021
Q1 		$18K Buy
32
+12
+60% +$7.99K ﹤0.01% 3952
2020
Q4 		$14K Buy
+20
New +$9.74K ﹤0.01% 4082

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC)'s ALGS Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Aligos Therapeutics (ALGS) stake by 452% in Q2 2026, buying an estimated $1.82K and bringing the position to 359 shares worth $2.07K. The position accounts for ﹤0.01% of the portfolio, ranked #4725.

Tower Research Capital (TRC) first reported a position in ALGS in Q4 2020 and has held it in 20 quarters since. The position peaked at $30K in Q2 2021. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

  • Tower Research Capital (TRC) held 359 shares of Aligos Therapeutics worth $2.07K as of Q2 2026.
  • Tower Research Capital (TRC) bought 294 Aligos Therapeutics shares in Q2 2026, an estimated $1.82K.
  • Aligos Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4725 holding.
  • Tower Research Capital (TRC) first reported a position in Aligos Therapeutics in Q4 2020 and has held it in 20 quarters since.
  • Tower Research Capital (TRC)'s Aligos Therapeutics position peaked at $30K in Q2 2021.
  • 31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.